Satellos Bioscience (MSLE) Common Equity (2023 - 2026)
Satellos Bioscience (MSLE) posted quarterly Common Equity of $70.7 million for Q1 2026, up 154.33% quarter-over-quarter from $27.8 million in Q4 2025.
Satellos Bioscience (MSLE) Common Equity (2023 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Common Equity for 4 consecutive years, with $70.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity changed N/A year-over-year to $70.7 million; the TTM figure through Mar 2026 stood at $70.7 million (changed N/A YoY), while the FY2025 annual figure was $27.8 million, down 41.09% from the prior year.
- Common Equity advanced to $70.7 million in Q1 2026 per MSLE's latest filing, from $27.8 million in the prior quarter.
- Across five years, Common Equity topped out at $70.7 million in Q1 2026 and bottomed at $27.8 million in Q4 2025.
- Historically, Common Equity has averaged $44.2 million across 4 years, with a median of $39.2 million in 2023.
- Annual changes were most pronounced in 2024 — Common Equity surged 62.6% — and 2025, when it tumbled 42.81%.
- Satellos Bioscience's Common Equity stood at $29.9 million in 2023, then soared by 62.6% to $48.6 million in 2024, then sank by 42.81% to $27.8 million in 2025, then soared by 154.33% to $70.7 million in 2026.
- Business Quant data shows MSLE's Common Equity at $70.7 million in Q1 2026, $27.8 million in Q4 2025, and $48.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 9.79 Bn |
| 10 | Satellos Bioscience | 212.06 Mn | 212.06 Mn | - | 59.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.66 Mn |
| Dec 31, 2025 | 27.78 Mn |
| Dec 31, 2024 | 48.58 Mn |
| Dec 31, 2023 | 29.88 Mn |